Case ReportCase Report
Open Access

Intracerebral benign fibrous histiocytoma

Liusong Yang, Mingzhe Zheng, Yingfeng Zhu and Zhongqing Chen
Neurosciences Journal July 2024, 29 (3) 201-206; DOI: https://doi.org/10.17712/nsj.2024.3.202300116

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    - Timeline of clinical course and outcome for both BFH patients. BFH - benign fibrous histiocytoma

  • Figure 2
    Figure 2

    - Case 1 - Preoperative Imaging and Histopathological Analysis. (A) Gadolinium-enhanced MRI revealed a lesion in the left temporal region exhibiting heterogeneous enhancement. (B) Coronal T2-weighted MRI displayed no adherence to the dura mater. (C) MRS indicated maximal CHO/NAA ratios of 2.4. Panels (D) through (I) present IHC examination at 100× original magnification: (D) Hematoxylin and eosin (H&E) staining. (E) CD68 immunopositivity (positive cells indicated by arrows). (F) Vimentin immunopositivity (positive cells indicated by arrows). (G) Negative glial fibrillary acidic protein (GFAP) staining. (H) Negative epithelial membrane antigen (EMA) staining. (I) Weakly positive Ki-67 staining (positive cells indicated by arrows).

  • Figure 3
    Figure 3

    - Case 2 - Preoperative imaging and histopathological analysis. A) Gadolinium-enhanced MRI revealed a lesion in the right frontal region with heterogeneous enhancement. B) Axial T2-weighted MRI displayed peritumoral edema. C) MRS indicated maximal CHO/NAA ratios of 6.74. Panels (D) through (I) present IHC examination at 100× original magnification: D) H&E staining. E) Vimentin immunopositivity (positive cells indicated by arrows). F) Smooth muscle actin (SMA) immunopositivity (positive cells indicated by arrows). G) Negative glial fibrillary acidic protein (GFAP) staining. H) Negative epithelial membrane antigen (EMA) staining. I) Weakly positive Ki-67 staining (positive cells indicated by arrows).

Tables

  • Table 1

    - Clinical features of intracerebral BFH. BFH- benign fibrous histiocytoma (BFH), M- male, F- female, R- right, L left

    Case reportsAge (years)SexLocationPresentationTreatmentOutcome
    Pimental et al.213MR frontal lobeSeizuresTotal resectionNo recurrence at 20 months; Alive
    Moliterno et al.16FL temporal lobeSeizuresTotal resectionNo recurrence at 18 months; Alive
    Chen et al.325FL frontal lobeSeizuresTotal resectionNo recurrence at 24 months; Alive
    Chen et al.334FR parietal lobeHeadache and seizuresTotal resectionNo recurrence at 24 months; Alive
    Present case 130FL temporal lobeHeadache, dizziness, and seizureTotal resectionNo recurrence at 65 months; Alive
    Present case 251MR frontal lobeSeizuresTotal resectionNo recurrence at 113 months; Alive
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section